secwatch.observer — SEC 8-K summary
======================================

Issuer:     AN2 Therapeutics, Inc. (ANTX)
CIK:        0001880438
Form:       8-K
Filed at:   2025-05-27T23:59:59+00:00
Accession:  0001193125-25-127595
Event type: other_material
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

AN2 Therapeutics stockholders elect three Class III directors and ratify PwC as auditor
--------------------------------------------------------------------------------

- Eric Easom, Stephanie Wong, and Joseph Zakrzewski elected as Class III directors for term expiring 2028.
- Easom received 13,983,213 votes for; Wong 10,584,641; Zakrzewski 10,928,200; each had 3,403,334 broker non-votes.
- Ratification of PricewaterhouseCoopers LLP as independent auditor passed with 23,736,942 votes for, 47,413 against, 144,085 abstentions.
- Approximately 79.50% of outstanding shares (23,928,440) represented at the meeting, constituting a quorum.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1880438/000119312525127595/0001193125-25-127595-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1880438/000119312525127595/d82533d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-127595

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer